FilingReader Intelligence

Otsuka corrects details of Taiho's Araris Biotech acquisition

March 27, 2025 at 11:06 PM UTCBy FilingReader AI

Otsuka Holdings (TSE:4578) has issued a correction to its March 17, 2025, announcement regarding Taiho Pharmaceutical's acquisition of Araris Biotech as a subsidiary. The initial announcement contained inaccuracies, prompting the revision. The corrected announcement revises details concerning Araris Biotech's major shareholders and shareholding ratios. Samsung Venture Investment Corporation holds 18.51%, Redalpine Capital S.C.S., SICAR, Compartment IV holds 13.16%, and 4BIO Ventures II L.P. holds 12.36%. The announcement also updates details of the counterparty, 4BIO Ventures II L.P, including its location at 86-90 Paul Street, London, its capital which is USD 91,996,171.72, its net assets which is USD 75,509,693.80 (unaudited, as of December 31, 2024), total assets which is USD 79,107,186.90 (unaudited, as of December 31, 2024) and the major shareholders and shareholding ratio, noting they are different professional investor clients, and no limited partner owns more than 25%. The acquisition reflects Taiho Pharmaceutical's strategy to strengthen its capabilities in next-generation ADC drug discovery.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

TSE:4578Tokyo Stock Exchange

News Alerts

Get instant email alerts when Otsuka Holdings publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →